Investing.com -- Cathie Wood’s ARK Venture Fund has confirmed its investment in Umoja’s Series C funding round. Umoja, a biotech firm, is currently working on a novel cancer treatment method. This innovative approach involves modifying a patient’s immune system in vivo, aiming to boost the body’s inherent ability to combat cancer.
The ARK Venture Fund’s decision to invest in Umoja signifies its confidence in the company’s groundbreaking approach to cancer therapy. Umoja’s ongoing research and development efforts aim to harness the body’s immune system to fight cancer more effectively. The details of the investment, including the amount and terms, were not disclosed.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.